Allogene Therapeutics (ALLO) Common Equity (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Common Equity data on file, last reported at $278.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 27.64% year-over-year to $278.9 million; the trailing twelve-month figure through Mar 2026 stood at $278.9 million (down 27.64% YoY), and the FY2025 full-year result was $292.5 million, down 30.71% from the prior year.
• Common Equity eased to $278.9 million in Q1 2026, from $292.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $865.3 million in Q1 2022 to a low of $278.9 million in Q1 2026.
• A 5-year average of $521.6 million and a median of $512.2 million in 2023 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 16.47% in 2025, while the deepest fall reached 33.1% in 2025.
• Tracing ALLO's Common Equity over 5 years: stood at $666.9 million in 2022, then fell by 23.19% to $512.2 million in 2023, then fell by 17.58% to $422.2 million in 2024, then tumbled by 30.71% to $292.5 million in 2025, then dropped by 4.67% to $278.9 million in 2026.
• Business Quant data shows ALLO's Common Equity at $278.9 million in Q1 2026, $292.5 million in Q4 2025, and $315.3 million in Q3 2025.